British cell and gene therapy firm Oxford Biomedica (LSE: OXB) has agreed terms with a subsidiary of Institut Mérieux for the acquisition of ABL Europe, for around $16 million.
A small European contract development and manufacturing organization (CDMO), ABL has specialist expertise in the development and manufacturing of solutions for biotechs and biopharma.
In buying the company, Oxford Biomedica is expanding its expertise in areas including viruses for gene therapy, oncolytic viruses and vaccine candidates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze